If you want a gentle and pH-balanced solution for rinsing and storing your soft contact lenses, then you should consider the Sensitive Eyes Contact Lens Solution by Bausch & Lomb. We have been ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy, to strengthen its clinical-stage pipeline, according to a press release.

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.